Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc (Tables)

9 Months Ended

Sep. 30, 2022

Business Combination and Asset Acquisition [Abstract]

Schedule of consideration

Fair value of Clinigence common shares at $6.40 per share	$	326,151,098
Fair value of Clinigence outstanding common stock options and warrants		120,875,452
Total consideration	$	447,026,550

Schedule of acquired assets and assumed liabilities

Cash and cash equivalents	$	12,716,228
Accounts receivable, net		2,127,076
Prepaid expenses and other current assets		127,384
Property and equipment, net		14,793
Right of use asset, net		86,989
Intangible assets, net		21,668,000
Goodwill		424,337,915
Accounts payable and accrued expenses		(3,966,100)
Deferred revenue		(92,111)
Convertible notes payable, net		(3,771,858)
Term note payable		(674,526)
Lease liability		(91,238)
Deferred tax liability		(5,456,002)
Assets acquired	$	447,026,550

Schedule of pro forma financial information

	Three months ended September 30				Nine months ended September 30
	2022		2021		2022		2021
Revenue	$	28,395,058	$	5,568,757	$	171,779,408	$	163,031,521
Net income (loss) attributable to Nutex Health Inc.		(422,517,803)		(2,290,240)		(434,709,956)		54,339,002